Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

SZU-MIN HSIEHLiu, Ming-CheMing-CheLiuChen, Yen-HsuYen-HsuChenLee, Wen-SenWen-SenLeeHwang, Shinn-JangShinn-JangHwangCheng, Shu-HsingShu-HsingChengKo, Wen-ChienWen-ChienKoHwang, Kao-PinKao-PinHwangWang, Ning-ChiNing-ChiWangLee, Yu-LinYu-LinLeeLin, Yi-LingYi-LingLinShih, Shin-RuShin-RuShihHuang, Chung-GueiChung-GueiHuangLiao, Chun-CheChun-CheLiaoLiang, Jian-JongJian-JongLiangChang, Chih-ShinChih-ShinChangChen, CharlesCharlesChenLien, Chia EnChia EnLienTai, I-ChenI-ChenTaiLin, Tzou-YienTzou-YienLin2022-05-252022-05-2520212213-2600https://scholars.lib.ntu.edu.tw/handle/123456789/612059MVC-COV1901, a recombinant protein vaccine containing pre-fusion-stabilised spike protein S-2P adjuvanted with CpG 1018 and aluminium hydroxide, has been shown to be well tolerated with a good safety profile in healthy adults aged 20-49 years in a phase 1 trial, and provided a good cellular and humoral immune responses. We present the interim safety, tolerability, and immunogenicity results of a phase 2 clinical trial of the MVC-COV1901 vaccine in Taiwan.en[SDGs]SDG3Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwanjournal article10.1016/S2213-2600(21)00402-1346555222-s2.0-85120182098WOS:000729806800025https://scholars.lib.ntu.edu.tw/handle/123456789/589810